Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …

Abstract Alzheimer's disease (AD), being the number one in terms of dementia burden, is an
insidious age-related neurodegenerative disease and is presently considered a global …

Importance Effects of antiamyloid agents, targeting either fibrillar or soluble monomeric
amyloid peptides, on downstream biomarkers in cerebrospinal fluid (CSF) and plasma are …

Background Astrocytes, also called astroglia, maintain homoeostasis of the brain by
providing trophic and metabolic support to neurons. They recycle neurotransmitters …

Objective To measure CSF levels of biomarkers reflecting microglia and astrocytes
activation, neuroinflammation, and cerebrovascular changes and study their associations …

Reactive astrocytes were identified as a component of senile amyloid plaques in the cortex
of Alzheimer's disease (AD) patients several decades ago. However, their role in AD …

To date, the development of disease-modifying therapies for Alzheimer's disease (AD) has
largely focused on the removal of amyloid beta Aβ fragments from the CNS. Proteomic …

Abstract Chitinase‐3‐like protein 1 (CHI3L1/YKL‐40) has long been known as a biomarker
for early detection of neuroinflammation and disease diagnosis of Alzheimer's disease (AD) …

Alzheimer's disease (AD) is a rapidly growing disease that affects millions of people
worldwide, therefore there is an urgent need for its early diagnosis and treatment. A huge …

Alzheimer's disease (AD) is a progressive neurodegenerative disease and is the most
common cause of dementia in an aging population. The majority of research effort has …